Cytoplasmic overexpression of ALCAM is prognostic of disease progression in breast cancer

Abstract

The data suggest that strong cytoplasmic ALCAM expression in primary breast cancer, as detected by immunohistochemistry, might be a new marker for a more aggressive breast cancer biology.

Loss of ALCAM expression is linked to adverse phenotype and poor prognosis in breast cancer: A TMA-based immunohistochemical study on 2,197 breast cancer patients

“…Over the last decade, alterations in ALCAM expression have been described in several other malignancies including bladder (6), colorectal (7), esophageal squamous cell (8), pancreatic (9), oral squamous cell (10) and ovarian cancer (11), neuroblastoma (12), prostate (13) and breast cancer (14,15). These data suggest that ALCAM expression is increased in some tumors and downregulated in others.…”

“…Some studies revealed an increased ALCAM expression to be associated with poor prognosis (15,17) or lymph node metastasis and local recurrence (18), while others found a decreased ALCAM expression to be linked to a poorer clinical course (14,19,20). One explanation for these conflicting data potentially lies in the relatively small number of breast cancer cases included in those studies, ranging from 56 to 347 (14,15,17,21). The aim of the present study was to clarify the prevalence and prognostic role of ALCAM expression in breast cancer using a pre-existing large-scale tissue microarray (TMA) including more than 2,000 breast cancer samples.…”

N-glycoprotein profiling of lung adenocarcinoma pleural effusions by shotgun proteomics

“…Second, multimerin-2 (Endoglyx-1) is a multisubunit glycoprotein of the vascular endothelium and may be associated with neoangiogenesis in melanoma metastases. 11 Third, CD166 (activated leukocyte-cell adhesion molecule, ALCAM) is a CD6 ligand, which is overexpressed in prostate, breast, and colon cancers 10 and controls invasive tumor growth. 23 Finally, lysosome-associated membrane glycoprotein-2 (LAMP-2, CD107b) is highly expressed in lung, protects the lysosomal membrane from autodigestion, and has been implicated in metastasis of pancreatic carcinoma.…”

Increased expression of ALCAM/CD166 in pancreatic cancer is an independent prognostic marker for poor survival and early tumour relapse

“…It is considered a prognostic marker in melanoma (van Kempen et al, 2000), prostate cancer (Kristiansen et al, 2005), breast cancer (King et al, 2004;Weichert et al, 2004;Burkhardt et al, 2006), colorectal cancer (Weichert et al, 2004), bladder cancer (Tomita et al, 2003), oesophageal squamous cell carcinoma (Verma et al, 2005) and ovarian cancer (Mezzanzanica et al, 2008). However, these data are quite inconsistent.…”

“…However, these data are quite inconsistent. In some tumour types membranous expression is associated with worse prognosis (Weichert et al, 2004), whereas in other tumour types cytoplasmic localisation of ALCAM is an adverse prognostic parameter (Burkhardt et al, 2006). In addition, increased (Tomita et al, 2003;Weichert et al, 2004;Kristiansen et al, 2005;Verma et al, 2005;Burkhardt et al, 2006) as well as reduced (King et al, 2004;Mezzanzanica et al, 2008) expression of ALCAM has been correlated with poor prognosis, depending on the tumour type.…”